CoreAge Rx vs altRX
Two GLP-1 providers, one scoreboard. We put CoreAge Rx and altRX head-to-head on the published Brief Score — the same six factors, scored the same way.
CoreAge Rx
altRX
FDA warning letter, June 2026 — issued to Trinity HealthCare Supply, LLC dba altRx. See the FDA's warning letter database.
The verdict
CoreAge Rx takes this head-to-head.
CoreAge Rx scores 94 to 65 on our six-factor Brief Score — CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.
That doesn't make altRX a bad call — it's best for readers comparing clinician-supported compounded care who can verify the full subscription term and the medical-disqualification exception. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Compare | CoreAge Rx | altRX |
|---|---|---|
| Brief Score | 94/100 (A) | 65/100 (C) |
| Semaglutide | From $79/mo Annual offer: 12 months paid upfront, from $948. Main site: from $99/mo; confirm the selected offer. Full price detailsFrom $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo | Confirm full subscription commitment Semaglutide advertised at $89/month; minimum term, supplied quantity and full first payment unconfirmed. Cancellation needs seventy-two hours before billing. Medical-disqualification refunds deduct services already used. Full price detailsCompounded semaglutide offered; complete selected-term quote unknown; advertises $89/month without the full initial charge or minimum commitment |
| Tirzepatide | From $129/mo Annual offer: 12 months paid upfront, from $1,548. Main site: from $149/mo; confirm the selected offer. Full price detailsFrom $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo | Confirm full subscription commitment Tirzepatide advertised at $149/month; minimum term, supplied quantity and full first payment unconfirmed. Cancellation needs seventy-two hours before billing. Filled medication and ordinary changes of mind are not refundable. Full price detailsCompounded tirzepatide offered; complete selected-term quote unknown; advertises $149/month without the full initial charge or minimum commitment |
| Coverage | US only; restrictions by state, confirmed at intake | Membership advertised in all fifty states and D.C.; prescribing authority, clinician and medication availability vary by location |
| Brand-name access | Not confirmed | Current named GLP-1 offers are compounded; branded fulfillment was not established. |
| Oral / sublingual | Injection only | Unconfirmed |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
CoreAge Rx: The checked annual-plan offer starts at $79/$129 per month on annual prepay; the main product pages still show $99/$149. Confirm the selected offer.
altRX: Advertisements show $89 semaglutide/$149 tirzepatide per month; confirm the full initial charge and minimum term. Renewal cancellation requires seventy-two hours.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.